InMode
InMode Ltd is an Israeli medical technology company developing minimally invasive radiofrequency (RF) energy aesthetic and wellness devices. The company manufactures surgical devices utilizing proprietary RFAL (Radio-Frequency Assisted Lipolysis) and hands-free RF technology for subdermal remodeling, skin tightening, body contouring, and gynecological wellness under brands like Morpheus8, BodyTite, and Evolve. Main revenue drivers comprise global commercial sales of medical RF workstations, single-use consumable treatment tips, and technical maintenance service retainers. InMode serves plastic surgeons, dermatologists, aesthetic physicians, gynecologists, and medical spas across North America, Europe, Asia, and Latin America. The company holds a market-leading global position in minimally invasive radiofrequency-assisted body contouring and subdermal remodeling technology. Headquartered in Yokneam, Israel, InMode Ltd is listed on the Nasdaq Stock Market.
4 of the funds FundTelligence covers report a position in InMode.
- Legal name
- InMode Ltd
- Sector
- Health Care
- Country
- Israel
- Funds holding it
- 4
Funds holding InMode
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.21 % (full portfolio disclosed, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)